KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Andreas Burchert, Franck E Nicolini, Philipp le Coutre, Susanne Saussele, Andreas Hochhaus, Evin Tuere, Stephan K Metzelder, Kim Pauck, Holger Garn, Hartmann Raifer, Magdalena Huber, Norbert Gattermann, Martina Crysandt, Philippe Schafhausen, Matthias Bormann, Markus P Radsak, Agnès Guerci-Bresler, Thomas Illmer, Maria E Goebeler, Peter Herhaus, Lino L Teichmann, Georg-Nikolaus Franke, Fabian Lang, Stefan W Krause, Robert Möhle, Martine Klausmann, Frank Stegelmann, Christoph Lutz, Gabriel Etienne, Andrea Stoltefuß, Joachim R Göthert, Thomas Ernst, Maisun Abu-Samra, Heinz-Gert Höffkes, Andreas Neubauer, Ying Wang, Paul Weiland, Clara Otto, Lea Kiessler, Theresa Weber, Lea Kroning, Andrea Nist, Thorsten Stiewe, Rüdiger Hehlmann, Behnaz Aminossadati, Michael Wittenberg, Kerstin Winterstein, Thomas Oellerich, Marcus Lechner, Markus Pfirrmann, Carmen Schade-Brittinger, Paul Klemm, Christian Michel

Leukemia 40(2) 410-417

PMID41526617
PMCIDPMC12875868
DOI10.1038/s41375-025-02859-1
发表日期2026-01-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Treatment-free remission (TFR) after discontinuation of ABL tyrosine kinase inhibitors (TKIs) is an important therapeutic goal in chronic myeloid leukemia (CML). Interferon-α (IFN) has been suggested to promote durable TFR. The phase 3 ENDURE trial (NCT03117816; EUDRA-CT 2016-001030-94) prospectively tested this hypothesis in patients with stable deep molecular remission after TKI therapy. A total of 203 patients were randomised 1:1 to receive ropeginterferon alfa-2b (ropeg-IFN; 100 µg subcutaneously every two weeks for 15 months, n = 95) or observation alone (n = 108) after TKI discontinuation. The primary endpoint was molecular relapse-free survival (MRFS), defined as time to loss of major molecular response (MMR) or death. At a median follow-up of 36 months, 25-month MRFS was 56% (95% confidence interval (CI), 45-66) with ropeg-IFN and 59% (95% CI, 49-68) with observation (hazard ratio (HR), 1.02; 95% CI, 0.68-1.55; P = 0.91). Among 83 patients with molecular data after TKI restart, 79 (95%) regained at least MMR, 78 within 12 months (median 3 months, interquartile range: 2-4 months). Ropeg-IFN was well tolerated (median administered dose of 92 µg, range 3-104), and no new safety signals were observed. Ropeg-IFN maintenance did not improve the probability of sustained TFR after TKI discontinuation.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2. Kaplan-Meier analysis of molecular relapse–free survival (MRFS) in the ENDURE trial. MRFS probabilities are shown for patients with CML who discontinued TKI therapy after one month and were randomized to receive either ropeginterferon alfa-2b (ropeg-IFN) maintenance for 15 months or surveillance. At months 7, 13, and 25 after randomization (corresponding to 6, 12, and 24 months after TKI discontinuation), MRFS probabilities were 73%, 64%, and 56% in the ropeg-IFN arm and 67%, 60%, and 59% in the surveillance arm, respectively. Numbers below the graph indicate patients at risk at each time point. CI confidence interval, HR hazard ratio.

Kaplan-Meier_analysis_of_molecular_relapse-free_survival_MRFS_in_the_ENDURE_trial

molecular relapse-free survival

Fig. 2 · Panel Kaplan-Meier_analysis_of_molecular_relapse-free_survival_MRFS_in_the_ENDURE_trial

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan-Meier_analysis_of_molecular_relapse-free_survival_MRFS_in_the_ENDURE_trial 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

Fig. 4

Fig. 4. Overall survival probability. There were three deaths in the trial. One patient died due to a cardiac arrest while in MMR. The cause of death was unknown for the second patient. A third patient died after falling from stairs. The latter two patients had regained deep molecular response at the level MR4 after re-commencing TKI therapy for MMR-loss. At 48 months, 53 patients were still under observation. CI confidence interval.

Overall_survival_probabilities

Overall survival

Fig. 4 · Panel Overall_survival_probabilities

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel Overall_survival_probabilities 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme jump曲线 1:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. CONSORT flow diagram of patient disposition in the ENDURE trial. Of 223 patients screened, 9 (4.0%) did not meet the eligibility criteria. A total of 214 patients (96%) were randomized to either ropeginterferon alfa-2b (AOP2014; n = 101) or surveillance ( n = 113). After randomization, 11 patients (4.9%) were excluded from the analysis. The final analysis population comprised 95 patients in the ropeg-IFN arm and 108 patients in the surveillance arm. COVID coronavirus disease, MMR major molecular remission, PegIFN pegylated interferon.
非 KM Figure
Fig. 3Fig. 3. Probabillities of reachievement of molecular remission after loss of MMR. Left panel: Median time to reachievement of MMR was 3.1 months in the ropeg-IFN group vs. 3.2 months in the placebo group. Right panel: Median time to MR [4] was 4.2 months in the ropeg-IFN group vs. 4.8. months in the placebo group. MMR, major molecular remission; MR [4], molecular remission BCR::ABL ≤ 0.01% according to international scale; TKI tyrosine kinase inhibitor.
非 KM Figure